Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
Abstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods This retrospective study evaluated 65 SCLC patients w...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4938 |
| _version_ | 1797950880591380480 |
|---|---|
| author | Ayako Shiono Hisao Imai Satoshi Wasamoto Takeshi Tsuda Yoshiaki Nagai Hiroyuki Minemura Yutaka Yamada Takayuki Kishikawa Yukihiro Umeda Hiroki Takechi Ou Yamaguchi Atsuto Mouri Kyoichi Kaira Hirokazu Taniguchi Koichi Minato Hiroshi Kagamu |
| author_facet | Ayako Shiono Hisao Imai Satoshi Wasamoto Takeshi Tsuda Yoshiaki Nagai Hiroyuki Minemura Yutaka Yamada Takayuki Kishikawa Yukihiro Umeda Hiroki Takechi Ou Yamaguchi Atsuto Mouri Kyoichi Kaira Hirokazu Taniguchi Koichi Minato Hiroshi Kagamu |
| author_sort | Ayako Shiono |
| collection | DOAJ |
| description | Abstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods This retrospective study evaluated 65 SCLC patients who received atezolizumab, carboplatin, and etoposide for ED‐SCLC in nine study institutions between August 2019 and September 2020. Clinical efficacy, assessed according to response rate and survival, and toxicity were compared between the elderly (n = 36 patients; median age: 74 years [range: 70–89 years]) and the non‐elderly group (n = 29 patients; median age: 67 years [range: 43–69 years]). Results The response rate was 73.8% (80.5% in the elderly group and 65.5% in the non‐elderly group). There was no significant difference in both the median progression‐free survival (5.5 months vs. 4.9 months, p = 0.18) and the median overall survival (15.4 months vs. 15.9 months, p = 0.24) between the elderly group and the non‐elderly group. The frequencies of grade ≥3 hematological adverse events in the elderly patients were as follows: decreased white blood cells, 36.1%; decreased neutrophil count, 61.1%; decreased platelet count, 8.3%; and febrile neutropenia, 8.3%. One treatment‐related death due to lung infection occurred in the elderly group. Conclusion Despite hematologic toxicities, especially decreased neutrophil count, atezolizumab, carboplatin, and etoposide combination chemotherapy demonstrates favorable effectiveness and acceptable toxicity in elderly patients. Thus, atezolizumab plus carboplatin and etoposide could be the preferred standard treatment modality for elderly patients with ED‐SCLC. |
| first_indexed | 2024-04-10T22:22:01Z |
| format | Article |
| id | doaj.art-7b714a5a6ae74295a24b9195992b391e |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T22:22:01Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-7b714a5a6ae74295a24b9195992b391e2023-01-17T17:10:24ZengWileyCancer Medicine2045-76342023-01-01121738310.1002/cam4.4938Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancerAyako Shiono0Hisao Imai1Satoshi Wasamoto2Takeshi Tsuda3Yoshiaki Nagai4Hiroyuki Minemura5Yutaka Yamada6Takayuki Kishikawa7Yukihiro Umeda8Hiroki Takechi9Ou Yamaguchi10Atsuto Mouri11Kyoichi Kaira12Hirokazu Taniguchi13Koichi Minato14Hiroshi Kagamu15Department of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanDepartment of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanDivision of Respiratory Medicine Saku Central Hospital Advanced Care Center Saku JapanDivision of Respiratory Medicine Toyama Prefectural Central Hospital Toyama JapanDepartment of Respiratory Medicine Jichi Medical University, Saitama Medical Center Saitama JapanDepartment of Pulmonary Medicine Fukushima Medical University Fukushima JapanDivision of Respiratory Medicine Ibaraki Prefectural Central Hospital Kasama JapanDivision of Thoracic Oncology Tochigi Cancer Center Utsunomiya JapanThird Department of Internal Medicine, Faculty of Medical Sciences University of Fukui Eiheiji JapanDivision of Respiratory Medicine Saku Central Hospital Advanced Care Center Saku JapanDepartment of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanDepartment of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanDepartment of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanDivision of Respiratory Medicine Toyama Prefectural Central Hospital Toyama JapanDivision of Respiratory Medicine Gunma Prefectural Cancer Center Ota JapanDepartment of Respiratory Medicine, International Medical Center Saitama Medical University Hidaka JapanAbstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods This retrospective study evaluated 65 SCLC patients who received atezolizumab, carboplatin, and etoposide for ED‐SCLC in nine study institutions between August 2019 and September 2020. Clinical efficacy, assessed according to response rate and survival, and toxicity were compared between the elderly (n = 36 patients; median age: 74 years [range: 70–89 years]) and the non‐elderly group (n = 29 patients; median age: 67 years [range: 43–69 years]). Results The response rate was 73.8% (80.5% in the elderly group and 65.5% in the non‐elderly group). There was no significant difference in both the median progression‐free survival (5.5 months vs. 4.9 months, p = 0.18) and the median overall survival (15.4 months vs. 15.9 months, p = 0.24) between the elderly group and the non‐elderly group. The frequencies of grade ≥3 hematological adverse events in the elderly patients were as follows: decreased white blood cells, 36.1%; decreased neutrophil count, 61.1%; decreased platelet count, 8.3%; and febrile neutropenia, 8.3%. One treatment‐related death due to lung infection occurred in the elderly group. Conclusion Despite hematologic toxicities, especially decreased neutrophil count, atezolizumab, carboplatin, and etoposide combination chemotherapy demonstrates favorable effectiveness and acceptable toxicity in elderly patients. Thus, atezolizumab plus carboplatin and etoposide could be the preferred standard treatment modality for elderly patients with ED‐SCLC.https://doi.org/10.1002/cam4.4938atezolizumab plus carboplatin and etoposideelderly patientsimmune checkpoint inhibitorsmall‐cell lung cancer |
| spellingShingle | Ayako Shiono Hisao Imai Satoshi Wasamoto Takeshi Tsuda Yoshiaki Nagai Hiroyuki Minemura Yutaka Yamada Takayuki Kishikawa Yukihiro Umeda Hiroki Takechi Ou Yamaguchi Atsuto Mouri Kyoichi Kaira Hirokazu Taniguchi Koichi Minato Hiroshi Kagamu Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer Cancer Medicine atezolizumab plus carboplatin and etoposide elderly patients immune checkpoint inhibitor small‐cell lung cancer |
| title | Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer |
| title_full | Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer |
| title_fullStr | Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer |
| title_full_unstemmed | Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer |
| title_short | Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer |
| title_sort | real world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive disease small cell lung cancer |
| topic | atezolizumab plus carboplatin and etoposide elderly patients immune checkpoint inhibitor small‐cell lung cancer |
| url | https://doi.org/10.1002/cam4.4938 |
| work_keys_str_mv | AT ayakoshiono realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT hisaoimai realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT satoshiwasamoto realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT takeshitsuda realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT yoshiakinagai realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT hiroyukiminemura realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT yutakayamada realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT takayukikishikawa realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT yukihiroumeda realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT hirokitakechi realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT ouyamaguchi realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT atsutomouri realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT kyoichikaira realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT hirokazutaniguchi realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT koichiminato realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer AT hiroshikagamu realworlddataofatezolizumabpluscarboplatinandetoposideinelderlypatientswithextensivediseasesmallcelllungcancer |